VivoSeq
Infectious Disease

Drug-Resistant Tuberculosis

9

Pipeline Programs↗

1

Active Trials↗

6

Companies Involved↗

Drug-Resistant Tuberculosis is an early-stage landscape with 9 programs across 6 companies. The most active players are Otsuka, Karuna Therapeutics, Inc., a Bristol Myers Squibb company, Bayer. 2 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

35/100

Pipeline Velocity

6/100

Mech. Concentration

20/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Otsuka logo

Otsuka

1 program

Phase 2K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

ApprovedBayer logo

Bayer

1 program

ApprovedNovartis logo

Novartis

1 program

PreclinicalPfizer logo

Pfizer

1 program

PreclinicalP

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

2

clinical trials

Not yet recruiting1 · 50%
Completed1 · 50%

Clinical Trials

Trial Activity

A Study on the Short-course Treatment Regimen Containing Pretomanid for Drug-resistant Tuberculosis
Not yet recruiting·WWuhan Pulmonary Hospital·N/A·NCT07126639·200 enrolled
FS-1 Drug for Treatment of Multiple Drug-resistant Tuberculosis
Completed·SScientific Center for Anti-infectious Drugs, Kazakhstan·Phase 3·NCT02607449·344 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)